Manufacturing

The biopharmaceutical landscape in 2026 operates as a high-stakes arena where the efficiency of protein production directly determines the accessibility of life-saving treatments for millions of patients. Central to this enterprise are Chinese hamster ovary (CHO) cells, which currently serve as the

The persistent challenge of managing generalized myasthenia gravis has long forced patients to rely on treatments that merely suppress symptoms rather than addressing the underlying immune dysfunction that causes debilitating muscle weakness. Kyverna Therapeutics and ElevateBio have recently

Trauma surgeons often face a race against time when a patient presents with a shattered limb or a ruptured artery where every second spent searching for a viable donor vein increases the risk of amputation or death. This high-pressure environment has long necessitated a surgical solution that

The landscape of national security has shifted dramatically as the United Kingdom realizes that biological hazards are no longer peripheral concerns but central pillars of sovereign defense. Since the implementation of the 2023 Biological Security Strategy, the nation has moved away from the

The pursuit of surgical solutions that prioritize long-term biological compatibility has led to a breakthrough in the field of soft tissue reconstruction with the successful completion of the latest clinical trials for the REGENERA breast scaffold. Unlike traditional synthetic implants that remain

The sudden detection of high-pathogenicity avian influenza within a commercial poultry facility in South Australia has sent ripples through the nation’s financial markets, highlighting the precarious nature of agricultural stability. This biological event serves as a stark reminder that biosecurity